Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.03%177.901.3%$462.90m
CELGCelgene Corporation
0.96%97.441.3%$422.15m
GILDGilead Sciences, Inc.
1.28%67.210.9%$393.48m
BIIBBiogen Inc.
2.07%232.391.3%$354.74m
ILMNIllumina, Inc.
1.66%349.713.5%$272.39m
REGNRegeneron Pharmaceuticals, Inc.
2.24%312.082.6%$234.12m
AAgilent Technologies, Inc.
0.81%70.541.6%$213.80m
VRTXVertex Pharmaceuticals Incorporated
2.09%173.781.9%$198.25m
ARRYArray BioPharma Inc.
56.49%46.318.2%$185.53m
EXASExact Sciences Corporation
0.88%110.7525.3%$184.49m
ALXNAlexion Pharmaceuticals, Inc.
2.55%120.942.0%$176.56m
BMRNBioMarin Pharmaceutical Inc.
4.35%84.364.3%$136.50m
MRTXMirati Therapeutics Inc.
6.33%100.232.5%$113.79m
IONSIonis Pharmaceuticals, Inc.
4.09%64.638.2%$96.90m
INCYIncyte Corporation
5.48%81.972.5%$92.09m

Company Profile

Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.